Gleamer appears in FDA device records as the applicant for ChestView US, filed under regulation 21 CFR 892.2070, product code MYN, device class 2, in the radiology advisory committee. The company's own published company page states that Gleamer was founded in Paris in 2017 and that BoneView obtained Class IIa CE marking in 2020. The U.S. record set reviewed here contains one linked 510(k) entry, K252486, decided substantially equivalent on September 9, 2026, with a decision date of September 9, 2026 and a Traditional clearance type. [1][2][8]
The ChestView US filing sequence
ChestView US version 1.0 was cleared under K241620, with the FDA letter dated February 27, 2025 and the device dated January 27, 2025. The later submission, K252486, covers ChestView US (1.1); the FDA record lists the applicant as Gleamer, the device as ChestView US (1.1), and the decision as SESE, substantially equivalent, dated September 9, 2026. The K252486 letter gives the regulation number as 21 CFR 892.2070, regulatory class II, product code MYN, and states the submission was dated and received August 10, 2026. [1][2][6]
The K252486 review documentation describes version 1.1 as sharing identical technological features, indications for use, intended users and workflow with the predicate ChestView US version 1.0 (K241620). Both versions are described as analyzing chest radiographs, identifying and categorizing regions of interest as Nodule, Pleural space abnormality, Mediastinum/Hila abnormality, or Consolidation, and as concurrent reading aids for radiologists and emergency medicine physicians interpreting chest radiographs. [2]
Documented scope of the software
Gleamer's published ChestView page describes the product as an AI solution for critical chest pathology that offers radiologists and emergency department doctors an automated second opinion on chest X-rays within the reading workflow. The page lists pleural space abnormalities, consolidations, nodules and mediastinal/hilar abnormalities among the findings the software assists in identifying. These are the manufacturer's descriptions of intended assistance, not statements of diagnostic performance. [5]
For K241620, the review documentation states that product verification and validation testing were conducted and documented per the FDA guidance on premarket submissions for device software functions at a Basic Documentation Level, with unit, integration and system-level nonclinical testing of the final software version. The same documentation states that software requirements and risk analysis were verified and traced. [6]
Regulatory identity and company context
FDA establishment registration and device listing records identify ChestView US under the classification name Analyzer, Medical Image, product code MYN, device class 2, regulation number 892.2070. The 510(k) database entry for K241620 records no combination product and no authorized predetermined change control plan. [7][9]
Gleamer's published company page states that the company was founded in Paris in 2017 to bring clinically validated AI into radiology workflows, and that it delivers CE and FDA-cleared AI solutions across X-ray, CT and MRI. Gleamer's published regulatory information page describes Gleamer Copilot as a marketing term encompassing all of Gleamer's solutions, with regulatory status listed per individual solution; it identifies BoneView, including BoneAge and BoneMetrics functionalities, as a Class IIa device assessed by notified body BSI CE 2797 under regulation 2017/745. [4][8]
What the record does and does not establish
The linked collection contains one 510(k) record, and that single record carries a substantially equivalent decision; this describes the reviewed filings only and is not a measure of total portfolio, sales or safety performance. The FDA filing address in Paris is an applicant contact address in the submission, not a verified corporate headquarters designation. Ownership, parent entities, customer lists and commercial availability in the United States are not established by these records. [1][2]

